<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03602898</url>
  </required_header>
  <id_info>
    <org_study_id>9954</org_study_id>
    <secondary_id>NCI-2018-01302</secondary_id>
    <secondary_id>9954</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <secondary_id>RG1001747</secondary_id>
    <nct_id>NCT03602898</nct_id>
  </id_info>
  <brief_title>Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation</brief_title>
  <official_title>A Randomized Phase II Study to Compare ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well 3 different drug combinations prevent graft versus host
      disease (GVHD) after donor stem cell transplant. Calcineurin inhibitors, such as cyclosporine
      and tacrolimus, may stop the activity of donor cells that can cause GVHD. Chemotherapy drugs,
      such as cyclophosphamide and methotrexate, may also stop the donor cells that can lead to
      GVHD while not affecting the cancer-fighting donor cells. Immunosuppressive therapy, such as
      anti-thymocyte globulin (ATG), is used to decrease the body's immune response and reduces the
      risk of GVHD. It is not yet known which combination of drugs: 1) ATG, methotrexate, and
      calcineurin inhibitor 2) cyclophosphamide and calcineurin inhibitor, or 3) methotrexate and
      calcineurin inhibitor may work best to prevent graft versus host disease and result in best
      overall outcome after donor stem cell transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To compare rates of chronic graft versus host disease (GVHD) between anti-thymocyte
      globulin (ATG) or post-transplantation cyclophosphamide (PTCy) to calcineurin inhibitor
      (CNI)-methotrexate.

      SECONDARY OBJECTIVES:

      I. To compare chronic GVHD, survival, GVHD-free relapse-free survival (GRFS), chronic
      GVHD-free relapse-free survival (CRFS), grade II-IV and III-IV acute GHVD, relapse, and
      non-relapse mortality between ATG and PTCy.

      OUTLINE:

      CONDITIONING REGIMENS:Participants receive 1 of 3 regimens and are randomized to 1 of 3 arms
      for GVHD prophylaxis.

      REGIMEN A: Participants undergo total body irradiation (TBI) on days -6 to -4 (-7 to -4 for
      those &lt; 18 years), then receive cyclophosphamide IV over 1-2 hours on days -3 and -2.
      Participants randomized to Arm 2 only receive TBI on days -3 to -1 (-4 to -1 for those &lt; 18
      years).

      REGIMEN B: Participants receive fludarabine phosphate IV and busulfan IV every 6 hours on
      days -5 to -2.

      REGIMEN C: Participants receive busulfan orally (PO) or IV every 6 hours on days -7 to -4 and
      cyclophosphamide IV over 1-2 hours on days -3 and -2.

      Myelofibrosis or other myeloproliferative neoplasms: Participants &gt;= 18 years receive
      cyclophosphamide IV over 1-2 hours on days -7 and -6 and busulfan IV on days -5 to -2.
      Participants &lt; 17 years receive busulfan IV every 6 hours on days -7 to -4 and
      cyclophosphamide IV on days -3 and -2.

      All participants undergo peripheral blood stem cell transplantation on day 0.

      ARM 1: Participants receive anti-thymocyte globulin IV over 4-6 hours on days -3 to -1.
      Beginning day -1, participants also receive tacrolimus IV or cyclosporine IV twice daily
      (BID) tapered at day 50, and methotrexate IV on days 1, 3, 6 and 11 in the absence of disease
      progression or unacceptable toxicity.

      ARM 2: Participants receive cyclophosphamide IV over 1-2 hours on days 3 and 4. Beginning day
      5, participants also receive tacrolimus IV or cyclosporine IV BID tapered at day 50 in the
      absence of disease progression or unacceptable toxicity.

      ARM 3: Beginning day -1, participants receive tacrolimus IV or cyclosporine IV BID tapered at
      day 50, and methotrexate IV on days 1, 3, 6 and 11 in the absence of disease progression or
      unacceptable toxicity.

      After completion of study treatment, participants are followed up at 6 months, then annually
      thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2020</start_date>
  <completion_date type="Anticipated">September 17, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 17, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Moderate to severe chronic graft versus host disease (GVHD) based on National Institute of Health 2014 consensus criteria</measure>
    <time_frame>At 1 year</time_frame>
    <description>Probabilities of chronic GVHD at one year will be compared using a chi-square test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>At 1 year post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GVHD-free relapse-free survival (GRFS)</measure>
    <time_frame>At 1 year post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic GVHD-free relapse-free survival (CRFS)</measure>
    <time_frame>At 1 year post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade II-IV acute GVHD</measure>
    <time_frame>At 100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade III-IV acute GVHD</measure>
    <time_frame>At 100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse</measure>
    <time_frame>At 1 year post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse mortality</measure>
    <time_frame>At 1 year post transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Acute Lymphoblastic Leukemia in Remission</condition>
  <condition>Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome</condition>
  <condition>Acute Myeloid Leukemia in Remission</condition>
  <condition>Blasts 5 Percent or Less of Bone Marrow Nucleated Cells</condition>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <condition>Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive</condition>
  <condition>Donor</condition>
  <condition>Minimal Residual Disease</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Myelofibrosis</condition>
  <condition>Myeloproliferative Neoplasm</condition>
  <condition>Recurrent Acute Myeloid Leukemia</condition>
  <condition>Recurrent Hodgkin Lymphoma</condition>
  <condition>Recurrent Non-Hodgkin Lymphoma</condition>
  <condition>Refractory Acute Myeloid Leukemia</condition>
  <condition>Therapy-Related Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm 1 (ATG, tacrolimus or cyclosporine, methotrexate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive conditioning regimen (see detailed description) and then undergo peripheral blood stem cell transplantation on day 0. Participants receive anti-thymocyte globulin IV over 4-6 hours on days -3 to -1. Beginning day -1, participants also receive tacrolimus IV or cyclosporine IV BID tapered at day 50, and methotrexate IV on days 1, 3, 6 and 11 in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 (cyclophosphamide, tacrolimus or cyclosporine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive conditioning regimen (see detailed description) and then undergo peripheral blood stem cell transplantation on day 0. Participants receive cyclophosphamide IV over 1-2 hours on days 3 and 4. Beginning day 5, participants also receive tacrolimus IV or cyclosporine IV BID tapered at day 50 in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3 (tacrolimus or cyclosporine, methotrexate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive conditioning regimen (see detailed description) and then undergo peripheral blood stem cell transplantation on day 0. Beginning day -1, participants receive tacrolimus IV or cyclosporine IV BID tapered at day 50, and methotrexate IV on days 1, 3, 6 and 11.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anti-Thymocyte Globulin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm 1 (ATG, tacrolimus or cyclosporine, methotrexate)</arm_group_label>
    <other_name>Antithymocyte Globulin</other_name>
    <other_name>Antithymocyte Serum</other_name>
    <other_name>ATG</other_name>
    <other_name>ATGAM</other_name>
    <other_name>ATS</other_name>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Arm 1 (ATG, tacrolimus or cyclosporine, methotrexate)</arm_group_label>
    <arm_group_label>Arm 2 (cyclophosphamide, tacrolimus or cyclosporine)</arm_group_label>
    <arm_group_label>Arm 3 (tacrolimus or cyclosporine, methotrexate)</arm_group_label>
    <other_name>1, 4-Bis[methanesulfonoxy]butane</other_name>
    <other_name>BUS</other_name>
    <other_name>Bussulfam</other_name>
    <other_name>Busulfanum</other_name>
    <other_name>Busulfex</other_name>
    <other_name>Busulphan</other_name>
    <other_name>CB 2041</other_name>
    <other_name>CB-2041</other_name>
    <other_name>Glyzophrol</other_name>
    <other_name>GT 41</other_name>
    <other_name>GT-41</other_name>
    <other_name>Joacamine</other_name>
    <other_name>Methanesulfonic Acid Tetramethylene Ester</other_name>
    <other_name>Methanesulfonic acid, tetramethylene ester</other_name>
    <other_name>Mielucin</other_name>
    <other_name>Misulban</other_name>
    <other_name>Misulfan</other_name>
    <other_name>Mitosan</other_name>
    <other_name>Myeleukon</other_name>
    <other_name>Myeloleukon</other_name>
    <other_name>Myelosan</other_name>
    <other_name>Mylecytan</other_name>
    <other_name>Myleran</other_name>
    <other_name>Sulfabutin</other_name>
    <other_name>Tetramethylene Bis(methanesulfonate)</other_name>
    <other_name>Tetramethylene bis[methanesulfonate]</other_name>
    <other_name>WR-19508</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm 1 (ATG, tacrolimus or cyclosporine, methotrexate)</arm_group_label>
    <arm_group_label>Arm 2 (cyclophosphamide, tacrolimus or cyclosporine)</arm_group_label>
    <arm_group_label>Arm 3 (tacrolimus or cyclosporine, methotrexate)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Arm 1 (ATG, tacrolimus or cyclosporine, methotrexate)</arm_group_label>
    <arm_group_label>Arm 2 (cyclophosphamide, tacrolimus or cyclosporine)</arm_group_label>
    <arm_group_label>Arm 3 (tacrolimus or cyclosporine, methotrexate)</arm_group_label>
    <other_name>27-400</other_name>
    <other_name>Ciclosporin</other_name>
    <other_name>CsA</other_name>
    <other_name>Cyclosporin</other_name>
    <other_name>Cyclosporin A</other_name>
    <other_name>Gengraf</other_name>
    <other_name>Neoral</other_name>
    <other_name>OL 27-400</other_name>
    <other_name>Sandimmun</other_name>
    <other_name>Sandimmune</other_name>
    <other_name>SangCya</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm 1 (ATG, tacrolimus or cyclosporine, methotrexate)</arm_group_label>
    <arm_group_label>Arm 2 (cyclophosphamide, tacrolimus or cyclosporine)</arm_group_label>
    <arm_group_label>Arm 3 (tacrolimus or cyclosporine, methotrexate)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
    <other_name>SH T 586</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm 1 (ATG, tacrolimus or cyclosporine, methotrexate)</arm_group_label>
    <arm_group_label>Arm 3 (tacrolimus or cyclosporine, methotrexate)</arm_group_label>
    <other_name>Abitrexate</other_name>
    <other_name>Alpha-Methopterin</other_name>
    <other_name>Amethopterin</other_name>
    <other_name>Brimexate</other_name>
    <other_name>CL 14377</other_name>
    <other_name>CL-14377</other_name>
    <other_name>Emtexate</other_name>
    <other_name>Emthexat</other_name>
    <other_name>Emthexate</other_name>
    <other_name>Farmitrexat</other_name>
    <other_name>Fauldexato</other_name>
    <other_name>Folex</other_name>
    <other_name>Folex PFS</other_name>
    <other_name>Lantarel</other_name>
    <other_name>Ledertrexate</other_name>
    <other_name>Lumexon</other_name>
    <other_name>Maxtrex</other_name>
    <other_name>Medsatrexate</other_name>
    <other_name>Metex</other_name>
    <other_name>Methoblastin</other_name>
    <other_name>Methotrexate LPF</other_name>
    <other_name>Methotrexate Methylaminopterin</other_name>
    <other_name>Methotrexatum</other_name>
    <other_name>Metotrexato</other_name>
    <other_name>Metrotex</other_name>
    <other_name>Mexate</other_name>
    <other_name>Mexate-AQ</other_name>
    <other_name>MTX</other_name>
    <other_name>Novatrex</other_name>
    <other_name>Rheumatrex</other_name>
    <other_name>Texate</other_name>
    <other_name>Tremetex</other_name>
    <other_name>Trexeron</other_name>
    <other_name>Trixilem</other_name>
    <other_name>WR-19039</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Transplantation</intervention_name>
    <description>Undergo peripheral blood stem cell transplantation</description>
    <arm_group_label>Arm 1 (ATG, tacrolimus or cyclosporine, methotrexate)</arm_group_label>
    <arm_group_label>Arm 2 (cyclophosphamide, tacrolimus or cyclosporine)</arm_group_label>
    <arm_group_label>Arm 3 (tacrolimus or cyclosporine, methotrexate)</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>PBSCT</other_name>
    <other_name>Peripheral Blood Progenitor Cell Transplantation</other_name>
    <other_name>Peripheral Stem Cell Support</other_name>
    <other_name>Peripheral Stem Cell Transplant</other_name>
    <other_name>Peripheral Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm 1 (ATG, tacrolimus or cyclosporine, methotrexate)</arm_group_label>
    <arm_group_label>Arm 2 (cyclophosphamide, tacrolimus or cyclosporine)</arm_group_label>
    <arm_group_label>Arm 3 (tacrolimus or cyclosporine, methotrexate)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm 1 (ATG, tacrolimus or cyclosporine, methotrexate)</arm_group_label>
    <arm_group_label>Arm 2 (cyclophosphamide, tacrolimus or cyclosporine)</arm_group_label>
    <arm_group_label>Arm 3 (tacrolimus or cyclosporine, methotrexate)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Arm 1 (ATG, tacrolimus or cyclosporine, methotrexate)</arm_group_label>
    <arm_group_label>Arm 2 (cyclophosphamide, tacrolimus or cyclosporine)</arm_group_label>
    <arm_group_label>Arm 3 (tacrolimus or cyclosporine, methotrexate)</arm_group_label>
    <other_name>FK 506</other_name>
    <other_name>Fujimycin</other_name>
    <other_name>Hecoria</other_name>
    <other_name>Prograf</other_name>
    <other_name>Protopic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total-Body Irradiation</intervention_name>
    <description>Undergo TBI</description>
    <arm_group_label>Arm 1 (ATG, tacrolimus or cyclosporine, methotrexate)</arm_group_label>
    <arm_group_label>Arm 2 (cyclophosphamide, tacrolimus or cyclosporine)</arm_group_label>
    <arm_group_label>Arm 3 (tacrolimus or cyclosporine, methotrexate)</arm_group_label>
    <other_name>Total Body Irradiation</other_name>
    <other_name>Whole-Body Irradiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The following diseases will be permitted, although other diagnoses can be considered
             if approved by Fred Hutch Patient Care Conference or the participating institution's
             patient review committees and the principal investigator:

               -  Acute lymphocytic leukemia (ALL) in complete remission (CR)1 with high risk
                  features defined as evidence of adverse cytogenetics such as t(9;22), t(1;19),
                  t(4;11), or MLL rearrangements or presence of minimal residual disease

               -  Acute myeloid leukemia (AML) in CR1 with high risk features defined as:

                    -  Intermediate or adverse risk disease as defined by European LeukemiaNet
                       (ELN) 2017

                    -  Greater than 1 cycle of induction therapy required to achieve remission

                    -  Preceding myelodysplastic syndrome (MDS) or myelofibrosis

                    -  Therapy-related AML

                    -  Presence of FLT3 internal tandem duplications

                    -  French-American-British (FAB) M6 or M7 classification

               -  Acute leukemia (ALL or AML) in second (2nd) or greater CR (CR &gt; 2)

               -  Refractory or relapsed AML with =&lt; 5% bone marrow blasts and no circulating
                  blasts by morphology or proven extramedullary disease

               -  Myelodysplastic syndrome (MDS) with following high risk features: poor
                  cytogenetics (-7, inv(3)/t(3q)/del(3q), del(7q) or complex cytogenetics defined
                  as &gt;= 3 abnormalities), Revised International Prognostic Scoring System (IPSS-R)
                  risk group intermediate or higher, or treatment-related MDS

               -  Any phase of MDS if patient is &lt; 21 years of age

               -  Chronic myelogenous leukemia (CML) beyond 1st chronic phase or resistant to
                  tyrosine kinase inhibitors (adults)

               -  Chronic myelomonocytic leukemia (CMML)

               -  Myeloproliferative disorders/myelofibrosis

               -  Hodgkin or non-Hodgkin lymphoma: relapsed chemotherapy-sensitive (complete or
                  partial response)

          -  Female patients must have negative beta-human chorionic gonadotropin (HCG) pregnancy
             test (all women of child bearing-potential must have test performed)

          -  Ability to understand and the willingness to sign a written informed consent document

          -  For patients with acute leukemia, CR is defined as =&lt; 5% marrow blasts by morphology.
             CR with incomplete count recovery is allowed

          -  DONOR INCLUSION

          -  Unrelated donors matched for human leukocyte antigen (HLA)-A, B, C, DRB1 and DQB1 by
             high resolution typing

          -  Donors are excluded when preexisting immunoreactivity is identified that would
             jeopardize donor hematopoietic cell engraftment. This determination is based on the
             standard practice of the individual institution. The recommended procedure for
             patients with 10 of 10 HLA allele level (phenotypic) match is to obtain a panel
             reactive antibody (PRA) screens to class I and class II antigens for all patients
             before hematopoietic cell transplantation (HCT). If the PRA shows &gt; 10% activity, then
             flow cytometric or B and T cell cytotoxic cross matches should be obtained. The donor
             should be excluded if any of the cytotoxic cross match assays are positive

          -  Only granulocyte colony-stimulating factor (G-CSF) mobilized peripheral blood stem
             cell (PBSC) will be permitted as a hematopoietic stem cell (HSC) source on this
             protocol

          -  Donors must meet the selection criteria for administration of G-CSF and apheresis
             defined based on each institution's standard practice protocol for unrelated donors

          -  Donors must be capable of giving informed consent

        Exclusion Criteria:

          -  Prior autologous or allogeneic stem cell transplant

          -  Performance status: Karnofsky score &lt;60 or Lansky score &lt;50 for patients &lt;16 years old

          -  Uncontrolled infection. The protocol principal investigator (PI) will be final arbiter
             if there is uncertainty regarding whether a previous infection is under adequate
             control to allow enrollment in the study

          -  Positive serology for human immunodeficiency virus (HIV)-1, 2 or human T-lymphotropic
             virus (HTLV)-1, 2

          -  Left ventricular ejection fraction &lt; 45%. Uncontrolled arrhythmias or symptomatic
             cardiac disease

          -  Symptomatic pulmonary disease. Forced expiratory volume in 1 second (FEV1), forced
             vital capacity (FVC), diffusion capacity of the lung for carbon monoxide (DLCO) =&lt; 50%
             of predicted (corrected for hemoglobin). Use of continuous supplemental oxygen

          -  Calculated (Cockroft-Gault; or appropriate calculation for pediatric patients) serum
             creatinine clearance &lt;60 mL/min. If the calculated CrCl is 50-60 mL/min, but a
             measured CrCl by 24 hour urine collection is &gt; 60 mL/min, this measurement is
             acceptable

          -  Total serum bilirubin more than twice upper normal limit

          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) more than 3-fold
             higher than laboratory upper normal limits

          -  History of allergy or anaphylactic reaction to rabbit protein or to any product
             excipients

          -  Subjects may not be enrolled in other investigational trials with acute or chronic
             GVHD as the primary endpoint

          -  DONOR EXCLUSION

          -  Donor who will exclusively donate marrow

          -  Donors who are HIV-positive

          -  Potential donors who for psychological, physiological, or medical reasons cannot
             tolerate administration of G-CSF or apheresis

          -  Donors who are allergic to filgrastim or Escherichia (E.) coli-derived proteins

          -  Donor-related risks to recipients

          -  Positive anti-donor lymphocytotoxic crossmatch

          -  Pregnant or lactating women

          -  Prior malignancy within the last 5 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masumi Ueda</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Masumi Ueda</last_name>
      <phone>206-667-4546</phone>
    </contact>
    <investigator>
      <last_name>Masumi Ueda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>July 13, 2018</study_first_submitted>
  <study_first_submitted_qc>July 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2018</study_first_posted>
  <last_update_submitted>March 3, 2020</last_update_submitted>
  <last_update_submitted_qc>March 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
    <mesh_term>Neoplasm, Residual</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

